Kansas Medical Clinic, P.A.

Kansas Medical
Clinic, P.A.

WEST CLINIC

2200 SW 6th St.
Topeka, KS 66606

GASTROENTEROLOGY

Ashraf M. Sufi, MD
Shekhar Challa, MD
785.354.8518
785.354.1255 fax
Jerry Feagan, MD
785.233.3555
Laura Welborn, ARNP-C
Jill Scheuler, PA-C

NEUROLOGY

Parminder Chawla, MD
Saba Bejanishvili, MD
785.354.9300
785.233.4669 fax

PATHOLOGY

Qaiser Sufi, MD

DERMATOLOGY

2860 SW Mission Woods
Topeka, KS 66614
785.272.6860
785.272.5839 fax
Joseph Gadzia, MD
Michael Kucenic, MD
Cindy Feagan, ARNP-C
Krishna Schmidt, PA-C

Laser Institute of Kansas

785.273.6460

DERMATOLOGY

6333 Long Ave. Suite 360
Shawnee, KS 66216
913.631.6330
913.631.6222 fax
Donald V. Belsito, MD
Trisha A. Prossick, MD

We listen... We'll take our time... We'll make sure.

Kansas Medical Clinic Clinical Research

The staff at Kansas Medical Clinic is dedicated to the evaluation of new drug therapies, procedures, and medical devices being developed for the treatment of diseases and medical conditions that commonly affect the lives of our patients and their families.

By conducting clinical research trials, we can offer access to medications, procedures, and medical devices not otherwise available in this area.

We offer research studies for a wide range of indications including digestive health related concerns, dermatology and neurology.

If you are interested in learning more about participation in clinical research studies, please call Kim Scott, RN,CCRC at 785.354.8518 or by e-mail @ kscott@kmcpa.com.

Clinical Trials Now Enrolling
ULCERATIVE COLITIS CLINICAL STUDY

  • For subjects diagnosed with ulcerative colitis.
  • Male or Non-pregnant Female age 18 or older
  • Must have had at least one flare up in the past 18 months
  • Must be on stable dose of Asacol for the past 3 months
  • Last dose of antibiotics at least 30 days prior to screening
  • Last dose of steroids at least 90 days prior to screen
  • No treatment with immunomodulatory therapies within 90 days prior to screening
  • No biologic treatments within 90 days rior to screening
  • No history of alcohol or drug abuse within 6 months of screening
  • No documented history of hepatic disease

    • There are 5 required visits to the clinic over a 1 year period. and 1 additional phone call visit.
    • Requires lab draw for serum creatinine level 3 times during the study.
    • All study medication (Asacol) provided at no cost during the time you are participating in the study
    • All treatment procedures are at no cost during the study

SUBJECTS AT RISK FOR DEVELOPING GASTRIC ULCERS DUE TO CHRONIC NSAID USE

  • There are 2 studies, 1 comparing study drug with Naproxen: the other, with Arthrotec
For Males or Non-pregnant Females age 18 or older with a history of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis or other medical conditions expected to require daily NSAID therapy for at least 6 months.

Ages 19-49 Must have a documented history of an uncomplimented gastric or duodenal ulcer within past 5 years

Ages 50 or greater do not require prior ulcer history

Cannot have bipolar or schizophrenia

No history of drug or alcohol abuse in the past 3 months

  • There are 6 required visits for this study with monthly phone calls made between visits 4 and 6
  • There are 4 required Endoscopies (EGDs)
  • There are required labs drawn at 4 visits
  • All study medication is provided at no cost during the time you are participating in the trial
  • All treatment procedures are at no cost to subjects

If you are interested in learning more about participation in clinical research studies, please call Kim Scott, RN,CCRC at 785.354.8518 or by e-mail @ kscott@kmcpa.com.

For general information regarding research trials, please visit http://www/fda.gov/opacom/lowlit/cltr.html

 

EROSIVE ESOPHAGITIS (GERD)

  • Male or Non-pregnant female ages 18-75
  • History of GERD for 3 months prior to screening
  • Heartburn 2 days/week for 1 month prior to screening
  • Esophageal erosions based on  EGD taken within 14 days prior to enrollment
  • H.pylori  negative based on urea breath test
  • There are some medication and medical exclusions that will be screened for

This study requires several screening visits to complete lab work, urea breath test and EGD. Once study medication is dispensed, it is taken for four weeks then another EGD is performed to check status of healing.  If healing is obtained, study participation is completed with a 2 week follow up visit. If erosions are still present, you remain on study med for an additional 4 week. Another EGD is the performed.

  • There will be an optional extension phase for this study for maintenance
  • All study drug, procedures and labs are at no cost.
  • You may receive a stipend for travel

 

HEPATITIS C STUDY

  • Male or Non-pregnant female ages 18 or older
  • Must have genotype 1 non-cirrhotic chronic Hepatitis C and relapsed on prior Pegylated interferon/ribavirin based therapy
  • No histologic evidence of cirrhosis as demonstrated by a liver biopsy performed within the past two years.  (If biopsy has not been performed, study will allow for Dr. Challa to perform biopsy)
  • HCV RNA titer must be > 600,000 IU/mL
  • Hep B negative

This study requires screening visit and labs.  Participant must be able to come to the office for 7 consecutive days starting on a Tuesday to receive daily study med injection.  Numerous lab tests will also be performed
You will receive all procedures and study med at no cost to you and receive a stipend for participation.

 

PSORIASIS  STUDY

  • Male or Female
  • Diagnosis of Chronic to severe Plaque Psoriasis
  • Current treatment with or initiating treatment with Raptiva
  • Be willing and able to fully participate for duration and follow up of 5 years

This study is being conducted at the KMC Dermatology Center, 2860 SW Mission Woods, Topeka, Kansas.


© Kansas Medical Clinic, P.A. • 2200 SW 6th St., Topeka, KS 66606 • 785.354.8518 • www.kmcpa.com